Tags

Type your tag names separated by a space and hit enter

Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease.

Abstract

We report the first longitudinal analysis of cerebrospinal fluid (CSF) F2-isoprostanes (IsoPs), quantitative in vivo biomarkers of lipid peroxidation, in patients with mild Alzheimer's disease (AD). CSF F2-IsoPs (i) were significantly increased in patients followed over one year, (ii) correlated with some clinical indices of dementia following correction for variation in ventricular enlargement, and (iii) were significantly lower in patients who used both alpha-tocopherol and vitamin C.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department Neurology, Oregon Health and Sciences University, Portland, OR, USA.

    , , , ,

    Source

    MeSH

    Aged
    Alzheimer Disease
    Antioxidants
    Ascorbic Acid
    Biomarkers
    Cerebral Ventricles
    Disease Progression
    F2-Isoprostanes
    Female
    Humans
    Lipid Peroxidation
    Longitudinal Studies
    Male
    Mental Status Schedule
    Middle Aged
    Statistics as Topic
    alpha-Tocopherol
    tau Proteins

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't
    Research Support, U.S. Gov't, Non-P.H.S.
    Research Support, U.S. Gov't, P.H.S.

    Language

    eng

    PubMed ID

    15004331

    Citation

    Quinn, Joseph F., et al. "Suppression of Longitudinal Increase in CSF F2-isoprostanes in Alzheimer's Disease." Journal of Alzheimer's Disease : JAD, vol. 6, no. 1, 2004, pp. 93-7.
    Quinn JF, Montine KS, Moore M, et al. Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. J Alzheimers Dis. 2004;6(1):93-7.
    Quinn, J. F., Montine, K. S., Moore, M., Morrow, J. D., Kaye, J. A., & Montine, T. J. (2004). Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. Journal of Alzheimer's Disease : JAD, 6(1), pp. 93-7.
    Quinn JF, et al. Suppression of Longitudinal Increase in CSF F2-isoprostanes in Alzheimer's Disease. J Alzheimers Dis. 2004;6(1):93-7. PubMed PMID: 15004331.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. AU - Quinn,Joseph F, AU - Montine,Kathleen S, AU - Moore,Milar, AU - Morrow,Jason D, AU - Kaye,Jeffrey A, AU - Montine,Thomas J, PY - 2004/3/9/pubmed PY - 2004/9/24/medline PY - 2004/3/9/entrez SP - 93 EP - 7 JF - Journal of Alzheimer's disease : JAD JO - J. Alzheimers Dis. VL - 6 IS - 1 N2 - We report the first longitudinal analysis of cerebrospinal fluid (CSF) F2-isoprostanes (IsoPs), quantitative in vivo biomarkers of lipid peroxidation, in patients with mild Alzheimer's disease (AD). CSF F2-IsoPs (i) were significantly increased in patients followed over one year, (ii) correlated with some clinical indices of dementia following correction for variation in ventricular enlargement, and (iii) were significantly lower in patients who used both alpha-tocopherol and vitamin C. SN - 1387-2877 UR - https://www.unboundmedicine.com/medline/citation/15004331/Suppression_of_longitudinal_increase_in_CSF_F2_isoprostanes_in_Alzheimer's_disease_ L2 - https://content.iospress.com/openurl?genre=article&issn=1387-2877&volume=6&issue=1&spage=93 DB - PRIME DP - Unbound Medicine ER -